Avigan, a candidate drug for treating COVID-19, has not shown apparent efficacy in treating the respiratory disease in clinical trials so far, raising doubts about its approval by the end of this month as sought by the government, sources familiar with the matter said Tuesday.
Interim results of clinical tests of Avigan on COVID-19 patients reported to the health ministry did not provide clear evidence of the drug’s effectiveness in limiting the progression of the disease, they said.
Prime Minister Shinzo Abe has said he is hoping for the approval of Avigan, developed by a Fujifilm Holdings Corp. subsidiary, by the end of May, although some medical experts have voiced concerns about rushing to approve the drug, which is known to have potential side effects on the fetus when used by pregnant women.
The clinical trial data were reported by hospitals treating people showing mild or no symptoms. The Health, Labor and Welfare Ministry has been expecting that the data, along with results of other trials involving thousands of COVID-19 patients, will help lead to early approval, the sources said.
Fujifilm is also conducting clinical studies of the drug on COVID-19 patients.
“There is currently no data showing that Avigan has high efficacy,” said Daisuke Tamura, an associate professor at Jichi Medical University specializing in pediatric infectious disease.
“It should be cautiously evaluated based on scientific evidence,” he said.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
Your news needs your support
Since the early stages of the COVID-19 crisis, The Japan Times has been providing free access to crucial news on the impact of the novel coronavirus as well as practical information about how to cope with the pandemic. Please consider subscribing today so we can continue offering you up-to-date, in-depth news about Japan.